Biogen licensed a new drug to treat stroke news American biotechnology company Biogen licensed from the company Remedy Pharmaceuticals an experimental preparation of Cyrara (glyburide for intravenous administration) for the treatment of an extensive hemispheric stroke. In the case of registration, this drug will be the first approved for 20 years of treatment for this disease, writes PharmaTimes. Currently, glyburide for intravenous administration is in phase III clinical trials.The company said that a promising drug could become the first in its class, allowing to significantly improve the outcome of the disease. Clinical studies of Phase II showed that the use of experimental drugs reduces the lethality of a large hemispheric stroke by 25% (the same figure in the placebo group - 7%). Nevertheless, the authors of the tests note that glyburide for intravenous administration failed to demonstrate effectiveness in reducing the number of surgical interventions. In modern medical practice, glyburide (a derivative of sulfonylureas of the second generation) in tableted form is successfully used in the treatment of type 2 diabetes. A source: Remedium